Drugs / Bifidobacterium animalis subsp. lactis
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00268164 | Jun 2004 → Mar 2007 | ulcerative colitis | Hvidovre University Hospital | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04187222 | Jul 2018 → Aug 2019 | mucositis | University of Sao Paulo | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04639141 | Dec 2021 → Apr 2022 | anxiety, autism spectrum disorder | The University of Queensland | Completed | No outcome recorded |
| — | NCT04701775 | Sep 2018 → Feb 2019 | hyperlipidemia | Eastern Mediterranean University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium animalis subsp. lactis | “Lactobacillus acidophilus (LA5) and Bifidobacterium animalis subsp. lactis (BB12)” NCT00268164 ↗ |
| Known as | BB12 | “A randomised double-blind placebo-controlled trial with Lactobacillus
acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for
maintenance of remission in...” PMID 21453880 ↗ Jan 20111“Lactobacillus acidophilus (LA5) and Bifidobacterium animalis subsp. lactis (BB12)” NCT00268164 ↗ |
| Modality | Other / unclassified | “Prebiotic + Probiotic” NCT04639141 ↗ |
| Route | Topical | “The gel was applied sub and supragingivally.” NCT04187222 ↗ |